.jpg "Hardik Mody, PhD photo")
Principal Scientist
Johnson and Johnson
Collegeville, Pennsylvania
Hardik is currently working as a Principal Scientist, PK/PD in the Preclinical Sciences and Translational Safety (PSTS) organization of Janssen R&D. In his current role, he supports early discovery, preclinical and early clinical development of therapeutic biologics in oncology and other therapeutic areas. He serves as the PK/PD SME (Subject Matter Expert) for cell and gene therapies within his organization. He also supports PK/PD modeling and simulation approaches to guide molecule design as well as rational FIH (First-In-Human) human dose selections for novel therapeutic modalities such as T-cell redirectors, monoclonal antibodies, antibody-drug conjugates, cell and gene therapies, along with others. Prior to Janssen, he was a Postdoctoral Associate at the Center for Pharmacometrics and Systems Pharmacology (CPSP) within the Department of Pharmaceutics at the University of Florida, where he worked extensively on PK/PD approaches for drug combinations in oncology as well as PBPK modeling of small molecules. Hardik is a Pharmacist and completed his graduate training (M.S. & Ph.D.) in Pharmaceutics from the Ohio State University College of Pharmacy. He has authored ~20 peer-reviewed scientific journal articles and several scientific abstracts in the field of PK/PD, oncology, and drug delivery.
Disclosure information not submitted.
Monday, October 17, 2022
3:00 PM – 4:00 PM ET
Tuesday, October 18, 2022
3:45 PM – 4:00 PM ET
Wednesday, October 19, 2022
3:00 PM – 4:00 PM ET